ESR1 and neoplasm: In the present study, we demonstrated that inhibition of CPT1A-mediated FAO with a CPT1 inhibitor re-sensitised ER-positive BC cells to tamoxifen therapy, which broadened the therapeutic effects of CPT1A/FAO inhibitors in tumours.